EWING, N.J., May 5, 2015 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (Nasdaq:ATRS) today announced it will release its first quarter 2015 financial results before the market opens on Monday, May 11, 2015, and host a webcast and conference call shortly thereafter at 8:30 a.m. ET (Eastern Time) to discuss the results. Eamonn P. Hobbs, President and Chief Executive Officer, will host the call.
The webcast of the conference call, which will include an interactive slide presentation, can be accessed through the link located on the "ATRS Investor Information" section of the Company's website (www.antarespharma.com) under the "Webcast" tab. Alternatively, callers may participate in the audio portion of the conference call by dialing 1-888-428-9473 (US), or 1-719-325-2362 (International). Callers should reference the Antares Pharma conference call or conference identification code 8070302. Callers can access the slide presentation on the "ATRS Investor Information" section of the Company's website under the "Presentations" tab. Webcast and telephone replays of the conference call will be available from 11:30 a.m. ET on Monday, May 11, 2015, through 11:30 a.m. ET on Tuesday, May 26, 2015. To access the replay, callers should dial 1-888-203-1112 (US) or 1-719-457-0820 (International) and enter passcode 8070302.
About Antares Pharma
Antares Pharma focuses on self-administered parenteral pharmaceutical products. The Company's product, OTREXUP™ (methotrexate) injection for subcutaneous use, is approved in the U.S. for the treatment of adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis and adults with severe recalcitrant psoriasis. Antares Pharma is also developing QuickShot® Testosterone for testosterone replacement therapy, and VIBEX® Sumatriptan for the acute treatment of migraines. The Company's technology platforms include VIBEX® disposable auto injectors, disposable multi-use pen injectors and reusable needle-free injectors. Antares Pharma has a multi-product deal with Teva Pharmaceutical Industries, Ltd. that includes VIBEX® epinephrine, exenatide multi-dose pen, and another undisclosed multi-dose pen. Our reusable needle-free injector for use with human growth hormone (hGH) is sold worldwide by Ferring B.V.